EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieKohortenstudieOpen Access

Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ : observational cohort study

Sabrina M Wang, Yan Li, Amanda Nash, Yi Ren, Samantha M Thomas, Amanda B Francescatti, Anne Barber, Thomas Lynch, Elizabeth S Frank, Lars J Grimm iD, Alastair M Thompson, Ann H Partridge und 3 weitere

British Journal of Surgery · 2024

DOI: 10.1093/bjs/znae198 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift British Journal of Surgery, 2024. Verfasst von Sabrina M Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Mastectomy, Segmental, Carcinoma, Intraductal, Noninfiltrating, Mastectomy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Patient-Centered Outcomes Research Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Breast-conserving surgery alone, breast-conserving surgery with adjuvant radiation treatment, and mastectomy are guideline-concordant treatments for ductal carcinoma in situ. The aim of this study was to compare survival outcomes between these treatment options.

Methods

A stratified random sample of patients diagnosed with pure ductal carcinoma in situ between 2008 and 2014 was selected from 1330 sites in the USA. Data on diagnosis, treatment, and follow-up were abstracted by local cancer registrars. Population-averaged marginal estimates of disease-specific survival and overall survival for breast-conserving surgery alone, breast-conserving surgery with radiation treatment, and mastectomy were obtained by combining sampling and overlap weights.

Results

A total of 18 442 women were included, with a median follow-up of 67.8 (interquartile range 46.1–93.5) months. A total of 35 women died from breast cancer, at a median age of 62 (interquartile range 50–74) years. Population-averaged 8-year rates of disease-specific survival were 99.6% or higher for all treatment groups, with no significant differences between groups (breast-conserving surgery alone versus breast-conserving surgery with radiation treatment, HR 1.19 (95% c.i. 0.29 to 4.85); and mastectomy versus breast-conserving surgery with radiation treatment, HR 1.74 (95% c.i. 0.53 to 5.72). There was no difference in overall survival between the patients who underwent a mastectomy and the patients who underwent breast-conserving surgery with radiation treatment (HR 1.09 (95% c.i. 0.83 to 1.43)). Patients who underwent breast-conserving surgery alone had lower overall survival compared with the patients who underwent breast-conserving surgery with radiation treatment (HR 1.29 (95% c.i. 1.00 to 1.67)). This survival difference vanished for all but one subgroup, namely patients less than 65 years (HR 1.86 (95% c.i. 1.15 to 3.00)).

Conclusion

There was no statistically significant difference in disease-specific survival between women operated with breast-conserving surgery alone, breast-conserving surgery with radiation treatment, or mastectomy for ductal carcinoma in situ. Given the low absolute risk of disease-specific mortality, these results provide confidence in offering individualized locoregional treatment without fear of compromising survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsMastectomy, SegmentalCarcinoma, Intraductal, NoninfiltratingMastectomyHumansFemaleMiddle AgedAgedRadiotherapy, AdjuvantUnited StatesTreatment Outcome

Autor:innen und Institutionen

  • Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
  • Duke Cancer Institute Biostatistics Shared Resource, Duke University Medical Center, Durham, North Carolina, USA.
  • Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
  • Cancer Programs, American College of Surgeons, Chicago, Illinois, USA.
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Department of Radiology, Duke University Medical Center, Durham, North Carolina, USA.

ORCID-Profile: Lars J Grimm

Förderung

  • NCI NIH HHS
  • Patient-Centered Outcomes Research Institute
  • National Institutes of Health
  • Department of Defence
  • Breast Cancer Research Foundation

Zitieren

APA

Wang, S. M., Li, Y., Nash, A., Ren, Y., Thomas, S. M., Francescatti, A. B., Barber, A., Lynch, T., Frank, E. S., Grimm, L. J., Thompson, A. M., Partridge, A. H., Hyslop, T., Hwang, E. S., & Ryser, M. D. (2024). Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ : observational cohort study. British Journal of Surgery. https://doi.org/10.1093/bjs/znae198

Vancouver

Wang SM, Li Y, Nash A, Ren Y, Thomas SM, Francescatti AB, et al. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ : observational cohort study. British Journal of Surgery. 2024. doi:10.1093/bjs/znae198

BibTeX
@article{Wang2024,
  author = {Wang, Sabrina M and Li, Yan and Nash, Amanda and Ren, Yi and Thomas, Samantha M and Francescatti, Amanda B and Barber, Anne and Lynch, Thomas and Frank, Elizabeth S and Grimm, Lars J and Thompson, Alastair M and Partridge, Ann H and Hyslop, Terry and Hwang, E Shelley and Ryser, Marc D},
  title = {Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ : observational cohort study},
  journal = {British Journal of Surgery},
  year = {2024},
  doi = {10.1093/bjs/znae198}
}
Kostenlos starten →